2009.09-2012.06，四川大学，华西药学院，药剂学，硕士

2012.09-2015.06，四川大学，生物治疗国家重点实验室，化学生物学，博士

2015.07-2019.03，电子科技大学附属医院·四川省人民医院，助理研究员

2015.10-2019.03，四川大学，生物治疗国家重点实验室，博士后（在职）

2017.01-2021.12，电子科技大学医学院，讲师

2019.04至今，电子科技大学附属医院·四川省人民医院，副研究员

2022.01至今，电子科技大学医学院，副教授

2022.05-2023.06，瑞典乌普萨拉大学，访问学者

第二届中国药理学会治疗药物监测研究专委会青年委员会委员

四川省抗癌协会肿瘤临床药学专委会常务委员

四川省药理学学会治疗药物监测研究专委会常务委员

四川省药理学学会理事会理事

成都药学会医院药学专委会常务委员

Current Medical Science期刊编委

Oncology Advances期刊编委。

作为项目负责人主持包括国家自然科学基金、中国博士后面上项目、四川省科技厅科研项目、四川省卫健委科研课题、成都市科技局课题，中央高校基金等在内的各级科研项目10余项。发表学术论文50余篇，其中，以一作或通讯作者身份发表SCI论文30余篇，IF>5分18篇，最高影响因子40.8，他引2000余次。申请发明专利4项，现已授权3项。作为项目完成人获四川省医学会医学科技一等奖和二等奖各1项。

近五年代表性成果如下：

1. Zhong L, et al. Discovery of 2-(Phenylamino)-6Hpyrimido[5,4-b][1,4]oxazin-7 (8H)-one Derivatives as Selective ACK1 Inhibitors with lmmunomodulatory Effects Enhancing Anti-PD-1 Therapy for Triple-Negative Breast Cancer. 2026, Accepted.

2. Zhang YR et al. VGLL4 Suppresses Malignant Phenotypes of Clear Cell Renal Cell Carcinoma Cells Through Modulation of Hippo/YAP and Wnt/β-Catenin Signaling Pathways. Biomedicines, 2026, 14: 2334. (通讯作者)

3. Ma TN, et al.. CZC54252 overcomes Osimertinib resistance by targeting EGFRC797S mutations. BMC Pharmacol Toxicol, 2026 27 (1): 84. (通讯)

4. Zhang YR, et al. PTPN2: Advances and perspectives in cancer treatment potential and inhibitor research. International Journal of Biological Macromolecules, 2025, 316:144740. (通讯)

5. Ma TN, et al. SETDB1: Progress and prospects in cancer treatment potential and inhibitor research. Bioorg Chem, 2024, 145: 107219. (通讯)

6. Hou YY, et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. NPJ Vaccines, 2024, 9 (1): 77. (通讯)

7. Zhong L, et al. Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study. Signal Transduct Target Ther, 2023, 8 (1): 363.

8. Peng HY, et al. Ganoderma lucidum: Current advancements of characteristic components and experimental progress in anti-liver fibrosis. Front Pharmacol, 2023, 13: 1094405. (并一)

9. Lu X, Zhong L, et al. Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death Dis, 2023, 14 (10): 676. (并一)

10. Jiang D, et al. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. Eur J Med Chem, 2023, 257: 115535. (并一)

11. Peng XR, et al. Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. Cancer Chemother Pharmacol, 2023, 91 (4): 303-315. (通讯)

12. Zhao ZP, et al. Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response. Front Pharmacol, 2022, 13: 1073713. (通讯)

13. Zhong L, et al. Recent advances in small-molecular therapeutics for COVID-19. Precision Clinical Medicine, 2022, 5: pbac024.

14. Peng XR, et al. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Drug Des Devel Ther, 2022, 16: 2639-2657. (通讯)

15. Zhong L, et al. Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives. Signal Transduction and Targeted Therapy, 2021, 6: 201.

16. Yang ZY, et al. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening  and activity evaluation. Bioorg Med Chem Lett, 2021,33: 127745. (通讯)

17. Peng XR et al. Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy, Signal Transduction and Targeted Therapy, 2021, 6 (1): 0-220. (通讯)

18. Su LY, et al. Anti-oral squamous cell carcinoma effects of a potent TAZ inhibitor AR-42. Journal of Cancer, 2020, 11(2): 364-373. (通讯)

19. Peng Q, et al. Association of elevated Yes-associated protein expression with gastric cancer and its clinicopathological features. J Biosci Med, 2020, 8, 96-109. (通讯)

20. Zhong L, et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Investigational New Drugs, 2019, 37: 616-624.

2023年入选四川省省级人才计划“天府青城计划”青年科技人才

2020年获批四川省卫健委学术技术带头人后备人选。